84 related articles for article (PubMed ID: 23692381)
21. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
22. Preclinical biodistribution and safety study of reduced expression in immortalized cells/Dickkopf-3-encoding adenoviral vector for prostate cancer gene therapy.
Sugimoto M; Watanabe M; Kaku H; Li SA; Noguchi H; Ueki H; Sakaguchi M; Huh NH; Nasu Y; Kumon H
Oncol Rep; 2012 Nov; 28(5):1645-52. PubMed ID: 22941469
[TBL] [Abstract][Full Text] [Related]
23. Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC.
Jantus-Lewintre E; Sanmartín E; Sirera R; Blasco A; Sanchez JJ; Tarón M; Rosell R; Camps C
Lung Cancer; 2011 Nov; 74(2):326-31. PubMed ID: 21481963
[TBL] [Abstract][Full Text] [Related]
24. Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.
Hemminki A; Kanerva A; Liu B; Wang M; Alvarez RD; Siegal GP; Curiel DT
Cancer Res; 2003 Feb; 63(4):847-53. PubMed ID: 12591736
[TBL] [Abstract][Full Text] [Related]
25. Preclinical safety evaluation of rAd5-hTERTC27 by intravenous injection.
Yue PJ; He L; Li Y; Shen QY; Li M; Huang DQ; Huang JJ; Peng Y
Regul Toxicol Pharmacol; 2013 Oct; 67(1):53-62. PubMed ID: 23827714
[TBL] [Abstract][Full Text] [Related]
26. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of ovarian tumor growth by gene therapy with recombinant soluble vascular endothelial growth factor receptor 2.
Wu Y; Li ZY; Zhao X; Kan B; Wei YQ
Hum Gene Ther; 2006 Sep; 17(9):941-8. PubMed ID: 16972762
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer.
Kinnunen K; Korpisalo P; Rissanen TT; Heikura T; Viita H; Uusitalo H; Ylä-Herttuala S
Acta Physiol (Oxf); 2006 Aug; 187(4):447-57. PubMed ID: 16866776
[TBL] [Abstract][Full Text] [Related]
30. Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovarian cancer cells to chemotherapeutic agents.
Tong X; Shine DH; Agoulnik I; Freund CT; Hasenburg A; Aguilar-Cordova E; Woo SL; Kieback DG
Anticancer Res; 1998; 18(5A):3421-6. PubMed ID: 9858918
[TBL] [Abstract][Full Text] [Related]
31. Low-dose simultaneous delivery of adenovirus encoding hepatocyte growth factor and vascular endothelial growth factor in dogs enhances liver proliferation without systemic growth factor elevation.
Atta HM; Al-Hendy A; Salama SA; Shaker OG; Hammam OA
Liver Int; 2009 Aug; 29(7):1022-30. PubMed ID: 19515220
[TBL] [Abstract][Full Text] [Related]
32. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
33. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.
Gao ZN; Wei YQ; Yang PS; Xu X; Zhao HQ; Huan X; Kang B
Oral Oncol; 2007 May; 43(5):477-83. PubMed ID: 16997614
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer.
Gurnani M; Lipari P; Dell J; Shi B; Nielsen LL
Cancer Chemother Pharmacol; 1999; 44(2):143-51. PubMed ID: 10412949
[TBL] [Abstract][Full Text] [Related]
35. Clinical usefulness of assessing VEGF and soluble receptors sVEGFR-1 and sVEGFR-2 in women with breast cancer.
Thielemann A; Baszczuk A; Kopczyński Z; Kopczyński P; Grodecka-Gazdecka S
Ann Agric Environ Med; 2013; 20(2):293-7. PubMed ID: 23772579
[TBL] [Abstract][Full Text] [Related]
36. Soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) is decreased in lung cancer patients showing progression: a pilot study.
Yilmaztepe A; Ulukaya E; Zik B; Yagci A; Sevimli A; Yilmaz M; Erdogan BB; Koc M; Akgoz S; Karadag M; Tokullugil A
Cancer Invest; 2007 Aug; 25(5):322-7. PubMed ID: 17661207
[TBL] [Abstract][Full Text] [Related]
37. [Gene therapy for ovarian cancers by adenovirus-mediated complete antibody gene].
Guo MG; Jiang MH; Yang Q; Li YM; Cui ZF; Li LF; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1147-51. PubMed ID: 15387973
[TBL] [Abstract][Full Text] [Related]
38. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion.
Garcia-Bañuelos J; Siller-Lopez F; Miranda A; Aguilar LK; Aguilar-Cordova E; Armendariz-Borunda J
Gene Ther; 2002 Jan; 9(2):127-34. PubMed ID: 11857071
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral-mediated delivery of the herpes simplex virus thymidine kinase gene selectively sensitizes human ovarian carcinoma cells to ganciclovir.
Rosenfeld ME; Feng M; Michael SI; Siegal GP; Alvarez RD; Curiel DT
Clin Cancer Res; 1995 Dec; 1(12):1571-80. PubMed ID: 9815958
[TBL] [Abstract][Full Text] [Related]
40. NTP Toxicology and Carcinogenesis Studies of 3,4-Dihydrocoumarin (CAS No. 119-84-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 423():1-336. PubMed ID: 12616288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
